Introduction
The Molecular Oncology Research Center “Centro de Pesquisa em Oncologia Molecular”
(CPOM) was inaugurated on August 19, 2010, by the former Minister of Health, Dr. José
Temporão. The CPOM is framed at the Institute for Research and Education “Instituto de
Ensino e Pesquisa” (IEP) of Barretos Cancer Hospital, which in conjunction with other clinical
departments of the Hospital, as well as the Department of Clinical Research and Postgraduation in Oncology, are the basic foundations in developing the future of oncology
medicine - personalized medicine.
The CPOM is installed in the new building of the IEP, with an area of 1,000 m2. The project
design was based on the most modern research centers, emphasizing the convenience of
movement, sharing of technological resources and the supervision of experience
professionals. The complex infrastructure of CPOM counts with state-of-the-art laboratories
of cytogenetics, molecular genetics, and molecular and cellular biology, allowing the
development of different research lines of in the field of molecular oncology.
During 2012, the second year of CPOM, we observed the growing of the projects generated
in the first year, and the implementation of numerous and varied scientific partnerships. A
significant number of researchers joined the Center, increasing its multidisciplinary, critical
mass and consequently productivity.
This year, the Hospital was included in the Outreach Program of St. Jude’s Children Hospital,
which will bring significant opportunities for research in pediatric oncology and has also
approved to be part of the International Cancer Genome Consortium (ICGC), an
international initiative to performed large scale next sequencing generation of cancer
worldwide, which puts the CPOM as a partner in a select group of institutions.
3
Molecular Oncology Research Center – Barretos Cancer Hospital
To evaluate and guide their steps, the CPOM was an External Advisory Board, which consists
of the following members:
- Jorge Reis-Filho (MSKCC, USA)
- Jorge Gomez (NCI, USA)
- Luisa Villa (INCT-CNPq, Brazil)
- Manuel Sobrinho-Simões (IPATIMUP, Portugal)
- Oliver Bogler (MDAnderson, USA)
1) Mission
To promote knowledge and innovation in order to apply molecular oncology in cancer
control.
- Knowledge of the causes, biological mechanisms and targets,
- Innovation in detection, diagnostic, treatment and prognosis,
- Application in prevention and assistance to patient.
2) Team
Senior Researcher
Adhemar Longatto Filho, PhD – Coordinator of Post-graduation
Andre Lopes Carvalho, PhD,MD – Executive Director IEP
Benedito Mauro Rossi, PhD,MD – External Collaborator
Ismael Dale Cotrim Guerreiro da Silva, PhD,MD – External Collaborator
José Humberto Tavares Guerreiro Fregnani, PhD, MD – Scientific Director of IEP
Luiz Fernando Lopes, PhD, MD – Coordinator of Pediatrics Department
Rui Manuel Reis, PhD, MD– Coordinator of CPOM
Visiting Professor
Kari J Syrianny, PhD, MD – Universidade de Turku, Kuusisto, Finlândia.
Jeremy Squire - Queens University, Kingston, Ontario, Canada
Junior Researcher
Cristovam Scapulatempo-Neto – Coordinator of Pathology Department
Daniel Onofre Vidal, PhD – Researcher CPOM
Denise Peixoto Guimarães, PhD, MD – Endoscopy Department
4
Molecular Oncology Research Center – Barretos Cancer Hospital
Edenir Palmero – Researcher CPOM
Henrique César S. Silveira– Researcher CPOM
Márcia Silveira – Researcher CPOM
Marjori Camparoto – Researcher CPOM
Vinicius Vazquez, PhD, MD – Skin Tumors Department
Post-doc
Adriane Feijó Evangelista, PhD
Ana Carolina Laus, PhD
Eduardo Anselmo Garcia, PhD
Fernanda Scarnato de Rosa, PhD
Lucas Tadeu Bidinotto, PhD
Olga Martinho, PhD
Vânia Sanmartino Mariano, PhD
Viviane Silva, PhD.
PhD Student
Adriana Tarlá Lorenzi
Aline Becker
Lidia Maria Rebolho Batista Arantes – external student
Ana Carolina Carvalho – external student
Master Student
Ana Laura Rodrigues Bordinhão
Augusto Ludvik Marino
Carla Aparecida Pinheiro
Croider Franco Lacerda
Flávia Coltri Eguchi
Letícia dos Santos Yamane
Maíra DeGiovani Stein
Natalia Campacci
Nathalia Campanella
Taciane Macedo
Biologist / Technician
Aline Tansine
5
Molecular Oncology Research Center – Barretos Cancer Hospital
Abel Feliciano de Queiroz Junior
Adriana Cruvinel Carloni (Master student)
Alessandra Paulino dos Santos
André Escremim de Paula
Carolina Dias Carlos (PhD student)
Eloisa Elena Faria Moreno
Deise Reis de Paula
Gabriela Carvalho Fernandes
Gustavo Noriz Berardinelli
Maicon Fernando Zanon da Silva (aluno de mestrado)
Marcela Nunes
Raul Torrieri
Renato José da Silva Oliveira (PhD student)
Valéria Mendes Motta
Research Initiation / Trainee
André de Lima Mota
Fatima Ramadan
Fernanda Cury
Graziela Sartori
Isabela de Carvalho
Juliana Oliveira de Lima
Lamis Ramadan
Talitha Lezaretti Blau
Administrative
Aline Cristina Morais – Assistant
Ednise Woyciechowski – Manager of IEP
Marcella Marchioretto – Financial Analyst of IEP
Osmar Alves – Informatics Technical Support
Raphael Ramos – Auxiliary
Rodolfo Massuda – Analyst
Paulo Ferreira – Marketing and Commercial
6
Molecular Oncology Research Center – Barretos Cancer Hospital
3) Research Lines
Cellular Signaling
One of the hallmarks of cancers is the oncogenic upregulation of the signaling cascades that
govern the transduction of extracellular growth factors to cellular nuclear response. Among
these plethora of players, receptor tyrosine kinases (RTKs) and intracellular MAPK,
PI3KCA/AKT and JAK/STAT pathways, have a crucial impact in cancer development, behavior
and currently, there is also an attractive therapeutic target. Our group is focused in evaluate
the major genetic alterations that disrupt these cellular circuits, and understand their
impact on patient prognosis and therapeutic response. Additionally, using tumor cell line
and primary culture models we intend to understand their function and biological impact on
cancer.
Biomarkers
We now know that cancer is a disease of the genome and this new vision has introduced a
new paradigm. In this scenario, the genome of the cancer can be more objectively in the
stratification of patients with cancer, leading to the emerging personalized medicine in
oncology. In order to achieve this aim, it is necessary to identify from the myriad of cancer
genomic changes, which ones have a clinical value - biomarkers. The diagnosis based on the
genome, it should present a high sensitivity and specificity, and detection of these
biomarkers should be possible not only in tumor tissue, but also extended to other body
fluids such as plasma, serum, urine, saliva, strokes cavity, allowing so early detection and
the ability to monitor tumor development. With a huge bank of tissues and fluids of cancer
patients in Barretos Hospital of Cancer (CrioBio) and a detailed medical history, our group
intends to validate potential biomarkers known in the Brazilian population, as well as
identify new biomarkers.
Functional Genomics of Cancer
The genomic science aims to understand how genes and genetic information is organized
within the genome (structural genomics) and how the organization determines its function
(functional genomics). The functional genomics applied to cancer aims to evaluate
7
Molecular Oncology Research Center – Barretos Cancer Hospital
systematically and simultaneously, the expression of genes (mRNA), microRNAs or proteins
to a better understanding of the molecular genetic basis governing the process of
carcinogenesis. Our research group intends to use the functional genomics resources for
transcriptional signatures mRNA and microRNAs expression in order to point out potential
molecular biomarkers of tumor progression. Additionally, using tumor cell line we can
validate the miRNA-mRNA interactions through functional tests using silencing of miRNAs
(using anti-miRNAs or anti-MIRs) and thus assess the impact of these new biomarkers in the
progression cancer.
Environmental factors and Cancer
The exposure to different types of environmental factors such as: food, occupational
conditions, medications, hormones, radiation, viruses, bacteria, chemical agents, air
pollution and water are intrinsically linked to the occurrence of cancer in exposed
populations. The determination of the potential cancer risk in the exposure to
environmental factors can contribute to public policies and preventive measures. Therefore,
our research group aims to assess populations exposed to chemical or environmental
factors using genetic biomarkers. Considering the susceptibility of each individual to
metabolize carcinogenic agents, we intend to reveal the molecular mechanisms involved in
the resistance to these compounds, polymorphisms, gene-environment interactions and its
implications in carcinogenesis.
Hereditary Cancer
Several cancers developed in higher than normal frequencies may be related to inherited
genetic alterations, present in predisposed families. Around 10% of most cancer types are
due to the presence of germline mutations, leading to an increased lifetime cancer risk. The
recognition of a hereditary cancer-affected individual is crucial for the identification of other
at-risk family members and their inclusion in cancer risk reduction strategies. The focus of
our research group is to prematurely identify, characterize and analyze, clinically and
molecularly, these at-risk individuals. Genetic modifiers that may contribute to an increased
cancer development risk, such as genetic polymorphisms, rearrangements, copy number
variations are also part of our research work.
8
Molecular Oncology Research Center – Barretos Cancer Hospital
-Epigenetic
Epigenetic are related to reversible events that do not produce modification in the genomic
DNA sequence, but rather alters its phenotype, influencing mechanisms related to gene
expression. Methylation is the most common epigenetic event, being a very important
biologic process involved in gene silencing. The study of hypermethylation can give vital
information on the understanding of carcinogenesis, as well as the evaluation of its pattern
can be used as a biomarker for diagnosis, treatment planning and prognosis of an individual.
Pediatric Tumor Biology
Although considered rare, childhood cancer is the leading cause of disease-related mortality
in children. Cancer in the childhood often is more devastating and aggressive than their
counterparts in adults. Despite the progress in cure rates and survival improvement
achieved in the last Decades, there is a group of tumors that still do not respond to any
available standard treatment. Our goal is to apply the knowledge and tools of molecular
biology to clarify and understand the biology and pathogenesis of pediatric tumors, in order
to identify potential biological markers that may support diagnosis and/or indicate
prognosis of pediatric patients. As well, we are looking for the altered pathways/genes that
can be targets for new therapy strategies
4) Productivity
4.1) Books or Book Chapters
1. Lopes LF, Almeida MTA. Tumores de Células Germinativas. In: Doenças neoplásicas da
criança e do adolescente, Editora Manole, pp.268-280, 2012.
2. Nogueira-de-Souza NC, Almeida JR, Serrano SV, Reis RM. BRAF in glioblastomas: clinical
implications. In: Glioblastoma: Risk Factors, Diagnosis and Treatment Options, Nova Science
Publishers, Inc, pp. 227-240, 2012.
3. Paixão Becker A, Caravina G, Clara C, Reis RM. The role of immunohistochemistry in the
diagnostic and prognostic of glioblastoma patients. In: Glioblastoma: Risk Factors, Diagnosis
and Treatment Options, Nova Science Publishers, Inc, pp. 173-199, 2012.
9
Molecular Oncology Research Center – Barretos Cancer Hospital
4. Viana-Pereira M, Jones C, Reis RM. Pediatric high grade glioma: role of microsatellite
instability. In “Diagnostic, Therapeutic and Prognostic: Pediatric Cancer”, vol 3, Part 4, 205210, 2012.
5. Vazquez VL, Serrano SV, Capuzzo R. Advanced squamous cell carcinoma of the skin. In:
Xiaoming Li. (Org.). Squamous Cell Carcinoma. 1ed.Rijeka: Intech, 2012, v. 01, p. 34-52.
6. Rossi BM, Ferreira FO, Silva FCC. Histórico, caracterização clínica e aspectos moleculares
da syndrome de Lynch. In: Tratado de Coloproctologia, Campos FGCM, Regadas FSP, Pinho
M. Atheneu, São Paulo, p.531-42, 2012.
4.2) Publications in international Journals
1. Almeida MI, Nicoloso M, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Bondaruk J, Fabbri M,
Czerniak B, Lanza G, Reis RM, Zweidler-McKay P, Calin GA. Strand-Specific miR-28-5p and
miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology. 2012 Apr;
142(4):886-896. IF: 12,032.
2. Almeida MI, Reis RM, Calin GA. Dec.oy activity through microRNAs: the therapeutic
implications. Expert Opin Biol Ther. 2012 Sep; 12(9):1153-9. IF: 3.505
3. Alves AL, Pereira CS, Carvalho Mde F, Fregnani JH, Ribeiro FQ. EGFR expression in
acquired middle ear cholesteatoma in children and adults. Eur J Pediatr. 2012
Feb;171(2):307-10.IF:1.879
4. Amorim R, Vilaca N, Martinho O, Reis RM, Sardo M, Rocha J, Fonseca AM, Baltazar F,
Neves IC. Zeolite structures loading with an anticancer compound as drug delivery systems.
Journal of Physical Chemistry C, 116, 48, 25642-25650, 2012. IF 4.805.
5. Begnami MD, Fregnani JH, Brentani H, Torres C, Costa WL Jr, Montagnini A, Nonogaki S,
Soares FA. Identification of protein expression signatures in gastric carcinomas using
clustering analysis. J Gastroenterol Hepatol. 2012 Feb;27(2):378-84. IF: 2.865.
6. Beldi MC, Tacla M, Caiaffa-Filho H, Ab'saber A, Siqueira S, Baracat EC, Alves VA, Longatto
Filho A. Implementing human papillomavirus testing in a public health hospital: challenges
and opportunities. Acta Cytologica. 2012; 56(2):160-5. IF: 0.488.
7. Bidinotto LT, Costa CA, Costa M, Rodrigues MA, Barbisan LS. Modifying Effects of
Lemongrass Essential Oil on Specific Tissue Response to the Carcinogen N-Methyl-NNitrosurea in Female BALB/c Mice. J Med Food. 2012 Feb; 15(2):161-8. IF: 1.408.
10
Molecular Oncology Research Center – Barretos Cancer Hospital
8. Bidinotto LT, de Cicco RL, Vanegas JE, Santucci-Pereira J, Vanden Heuvel JP, Washington S,
Aliaga C, Xu H, Russo IH, Manni A, El-Bayoumy K, Russo J. Fish oil alters tamoxifenmodulated expression of mRNAs that encode genes related to differentiation, proliferation,
metastasis, and immune response in rat mammary tumors. Nutr Cancer. 2012; 64(7):991-9
IF: 2,553.
9. Bravo-Calderón DM, Oliveira DT, Marana AN, Nonogaki S, Carvalho AL, Kowalski LP.
Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma.
Cancer Biomark. 2011-2012 10 (1):51-9. IF: 1,078.
10. Campa D, Martino A, Sainz J, Buda G, García Jamroziak K, Weinhold N, Reis RM, GarcíaSanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesuer F, Bugert P, Moreno V,
Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, Landi
S, Canzian F. Comprehensive investigation of genetic variation in the 8q24 region and
multiple myeloma risk in the IMMEnSE (International Multiple Myeloma rESEarch)
consortium. British Journal of Haematology, 2012 May; 157(3):331-8. IF: 4.941.
11. Cardeal LB, Boccardo E, Termini L, Rabachini T, Andreoli MA, di Loreto C, Longatto Filho
A, Villa LL, Maria-Engler SS. HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in
primary keratinocytes: possible implications in cervical carcinogenesis. PLoS One.
2012;7(3):e33585.IF 4.092.
12. Costa WL, Coimbra FJ, Fogaroli RC, Ribeiro HS, Diniz AL, Begnami MD, Mello CA, Fanelli
MF, Silva MJ, Fregnani JH, Montagnini AL. Adjuvant chemoradiotherapy after d2lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. Results of a
single cancer center. Radiat Oncol. 2012 Oct 15;7(1):169. IF: 2.321.
13. da Cunha IW, De Brot L, Carvalho KC, Rocha RM, Fregnani JH, Falzoni R, Ferreira Fde O,
Aguiar S Jr, Lopes A, Muto NH, Reis LF, Soares FA, Vassallo J. Prognostication of soft tissue
sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER2/neu, and survivin. Ann Surg Oncol. 2012 Jun; 19(6):1790-9. IF: 4.166.
14. de Carvalho AC, Kowalski LP, Campos AH, Soares FA, Carvalho AL, Vettore AL. Clinical
significance of molecular alterations in histologically negative surgical margins of head and
neck cancer patients. Oral Oncol. 2012 Mar; 48(3):240-8. IF: 2.857.
15. De Mello R, Costa BM, Reis RM, Hespanhol V. Insights into angiogenesis in non-small cell
lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent
Patents on Anti-Cancer Drug Discovery, 1; 7 (1):118-31. 2012. IF: 2.723.
11
Molecular Oncology Research Center – Barretos Cancer Hospital
16. De Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J,
Oliveira P, Hespanhol V, Reis RM. Association between EGF +61 genetic polymorphisms and
non-small cell lung cancer increased risk in a Portuguese population: a case-control study.
Tumour Biology. 2012 Oct; 33(5):1341-8. IF: 2.143.
17. De Molfetta GA, Ferreira CA, Vidal DO, de Rosso Giuliani L, Maldonado MJ, Silva WA Jr.
1031-1034delTAAC (Leu125Stop): a Novel Familial UBE3A Mutation Causing Angelman
Syndrome in Two Siblings showing Distinct Phenotypes. BMC Med Genet. 2012 Dec. 20;
13(1):124. IF: 2,328.
18. De Oliveira AT, Pinheiro C, Longatto Filho A, Brito MJ, Martinho O, Matos D, Carvalho
AL, Vazquez VL, Silva TB, Scapulatempo C, Saad SS, Reis RM, Baltazar F. Co-expression of
monocarboxylate transporter 1 (MCT1) with CD147 is associated with low survival in GIST
patients. Journal of Bioenergetics and Biomembranes, 2012 Feb; 44 (1):171-8. IF: 2.813.
19. Duprat Neto JP, Mauro AC, Molina AS, Nishinari K, Zurstrassen CE, Costa OF, Belfort FA,
Facure L, Fregnani JH. Isolated limb infusion with hyperthermia and chemotherapy for
advanced limb malignancy: factors influencing toxicity. ANZ J Surg. 2012 Sep 24. [Epub
ahead of print]. IF: 1.248.
20. Duprat Neto JP, Oliveira F, Bertolli E, Molina AS, Nishinari K, Facure L, Fregnani JH.
Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for
regional toxicity. Clinics (Sao Paulo). 2012;67(3):237-41. IF: 2.058.
21. Fanelli MF, Chinen LT, Begnami MD, Costa WL Jr, Fregnami JH, Soares FA, Montagnini
AL.
The
influence
of
transforming
growth
factor-α,
cyclooxygenase-2,
matrix
metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelialmesenchymal transition on overall survival of patients with gastric cancer. Histopathology.
2012 Aug; 61(2):153-61. IF: 3.082.
22. Fregnani JH, Scapulatempo C, Haikel Jr RL, Saccheto T, Campacci N, Mauad EC, Longatto
Filho A. Could Alarmingly High Rates of Negative Diagnoses in Remote Rural Areas Be
Minimized with Liquid-Based Cytology? Preliminary Results from the RODEO Study Team.
Acta Cytologica. 2012 Dec. 6; 57(1):69-74. IF: 0,488.
23. Haikel RL Jr, Mauad EC, Silva TB, Mattos JS, Chala LF, Longatto Filho A, Barros N.
Mammography-based screening program: preliminary results from a first 2-year round in a
Brazilian region using mobile and fixed units. BMC Womens Health. 2012 Oct 2; 12(1):32. IF:
1.28.
12
Molecular Oncology Research Center – Barretos Cancer Hospital
24. Hennes E, Zahn S, Lopes LF, Schomberger S, Leuschner I, Gobel U, Calaminus G,
Schneider DT. Molecular Genetic Analysis of Bilateral Ovarian Germ Cell Tumors. Clin
Pediatrics 2012 Oct; 224(6):359-365. IF: 1.151.
25. Kowalski LP, Sanabria A, Vartanian JG, Lima RA, Mendonca UBT, Santos CR, Boldrini D,
Mello LE, Pinto FP, Lehn CN, Correa LAC, Dedivitis RA, Guimarães AV, Pedruzzi PAG, Ramos
GHA, Gonçalves AJ, Suehara AB, Kanda JL, Capuzzo RC, Oliveira JC, Curado MP, Góis Filho JF,
Fukuyama E, Beserra Júnior I, Carvalho Neto PB, Carvalho AL. Total thyroiDec.tomy with
ultrasonic scalpel: a multicenter, randomized controlled trial. Head and Neck. 2012 Jun;
34(6):805-12. IF: 2.403.
26. Laus AC, Baratela WA, Laureano LA, Santos SA, Huber J, Ramos ES, Rebelo CC, Squire JA,
Martelli L. Karyotype/phenotype correlation in partial trisomies of the long arm of
chromosome 16: Case report and review of literature. Am J Med Genet A. 2012 Apr; 158A
(4):821-7. IF: 2,505.
27. Lima L, Dinis-Ribeiro M, Longatto Filho A, Santos L. Predictive Biomarkers of Bacillus
Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
Advances in Urology (Print), v. 2012, p. 1-17, 2012. IF: NA.
28. Longatto Filho A, Naud P, Derchain SF, Roteli-Martins C, Tatti S, Hammes LS, Sarian LO,
Eržen M, Branca M, de Matos JC, Gontijo R, Maeda MY, Lima T, Costa S, Syrjänen S, Syrjänen
K. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and
colposcopy in diagnosis of significant cervical pathology. Virchows Archiv. 2012 Jun;
460(6):577-85. IF: 2.491.
29. Longatto Filho A, Villa LL, Syrjänen K. Papillomavirus from the bench to the clinics.
Journal of Oncology. 2012; 2012:437438. IF: NA.
30. Lourenço AV, Fregnani CM, Silva PC, Latorre MR, Fregnani JH. Why are women with
cervical cancer not being diagnosed in preinvasive phase? An analysis of risk factors using a
hierarchical model. Int J Gynecol Cancer. 2012 May;22(4):645-53. IF: 1.646.
31. Marques H, Catarino R, Domingues N, Barros E, Portela C, Almeida MI, Costa S, Reis RM,
Medeiros R, Longatto Filho A. Detection of the Epstein-Barr virus in blood and bone marrow
mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not
associated with prognosis. Oncology Letters, 2012 Dec.;4(6):1285-1289. IF: 0.108.
32. Martino A, Campa D, Buda G, Sainz J, García Sanz R, Jamroziak K, Reis RM, Weinhold N,
Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Stein A, Kumar R, Orciuolo E, Gemignani F,
13
Molecular Oncology Research Center – Barretos Cancer Hospital
Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM. Polymorphisms in
xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and Multiple Myeloma Risk: a
case-control study in the context of the IMMEnSE (International Multiple Myeloma rESEarch)
consortium. Leukemia, 2012 Jun; 26(6):1419-22. IF: 9.561.
33. Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R,
Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S,
Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Genetics and molecular
epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J
Oncol. 2012 Mar; 40 (3): 625-38. IF: 2.399.
34. Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, García-Sanz R, Lesueur F,
Marques H, Moreno V, Jurado M, Ríos R, Szemraj-Rogucka Z, Szemraj J, Tjønneland A,
Overvad K, Vangsted AJ, Vogel U, Mikala G, Kádár K, Szombath G, Varkonyi J, Orciuolo E,
Dumontet C, Gemignani F, Rossi AM, Landi S, Petrini M, Houlston RS, Hemminki K, Canzian F.
Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple
myeloma. British Journal of Haematology, 2012 Sep; 158 (6):805-9. IF: 4.941.
35. Martinho O, Falopp C, Scapulatempo Neto C, Longatto Filho A, Baiocchib G, Cunha I,
Soares FA, Fregnanig JH, Reis RM. Loss of RKIP expression during the carcinogenic evolution
of endometrial cancer. Journal of Clinical Pathology, 2012 Feb; 65 (2):122-8. IF: 2.306.
36. Martinho O, Granja S, Jaraquemada T, Caeiro C, Miranda-Gonçalves V, Honavar M, Costa
P, Damasceno M, Rosner MR, Lopes JM, Reis RM. Downregulation of RKIP is associated with
poor outcome and malignant progression in gliomas. PLoS One. 2012; 7(1):e30769. IF: 4.092.
37. Martins TG, Trigo G, Fraga AG, Gama JB, Longatto Filho A, Saraiva M, Silva MT, Castro
AG, Pedrosa J. Corticosteroid-Induced Immunosuppression Ultimately Does Not
Compromise the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection.
PLoS Neglected Tropical Diseases. 2012 Nov; 6(11):e1925. IF: 4.716.
38. Oliveira AT, Pinheiro C, Longatto Filho A, Scapulatempo C, Matos D, Martinho O,
Vazquez VL, Carvalho AL, Saad SS, Brito MJ, Silva TB, Reis RM, Baltazar F. Co-expression of
monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low
survival in patients with gastrointestinal stromal tumors (GISTs). Journal of Bioenergetics
and Biomembranes, v.44, p. 171-178, 2012. IF: 2.813.
14
Molecular Oncology Research Center – Barretos Cancer Hospital
39. Oliveira DT, Biassi TP, Faustino SE, Carvalho AL, Landman G, Kowalski LP. Eosinophils
may predict occult lymph node metastasis in early oral cancer. Clin Oral Investig, 2012 Dec.;
16(6):1523-8. IF: 2.364.
40. Oliveira RDR, Fontana V, Junta CM, Marques MM, Macedo C, Rassi DM, Passos GAS,
Donadi EA, Louzada Jr, P. Differential gene expression profiles may differentiate responder
and non-responder rheumatoid arthritis patients for methotrexate monotherapy and
methotrexate plus TNF-blocker combined therapy. The Journal of Rheumatology, 2012, Aug
39(8); 1524-32. IF: 2, 91.
41. Pinheiro C, Longatto Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of
monocarboxylate transporters in human cancers: state of the art. Journal of Bioenergy and
Biomembrane. 2012 Feb; 44(1):127-39. IF: 2.813.
42. Pinheiro C, Longatto Filho A, Nogueira R, Schmitt F, Baltazar F. Lactate-induced IL-8
pathway in endothelial cells--letter. Cancer Research. 2012 Apr 1; 72(7):1901-2 IF: 7.856.
43. Pinheiro C, Longatto Filho A, Soares TR, Pereira H, Bedrossian C, Michael C, Schmitt FC,
Baltazar F. CD147 immunohistochemistry discriminates between reactive mesothelial cells
and malignant mesothelioma. Diagnostic Cytopathology. 2012 Jun; 40(6):478-83 IF: 1.160.
44. Santos EMM, Dominguez-Valentin M, Carneiro F, Oliveira LP, Ferreira FO, Nakagawa W
T, Gomy I, Ferraz VEF, Silva WA, Carraro DM, Rossi BM. Predictive models for mutations in
mismatch repair genes: implication for genetic counseling in developing countries. BMC
Cancer (Online) 2012 v. 12, p. 64-64. IF: 3.01.
45. Silva-Correia J, Miranda-Gonçalves V, Salgado AJ, Sousa N, Oliveira JM, Reis RM, Reis RL.
Angiogenic potential of gellan gum-based hydrogels for application in nucleus pulposus
regeneration: In vivo study. Tissue Eng Part A, 2012 Jun; 18 (11-12):1203-12.IF: 4.022.
(Journal cover).
46. Silveira VS, Canalle R, Scrideli CA, Queiroz RG, Lopes LF, Tone LG. CYP3A5 and NAT2
gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment
outcome. Molecular and Cellular Biochemistry, v. 364, p. 217-223, 2012. IF: 2,057.
47. Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto Filho A, Derchain S, Kozachenko V,
Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M,
Grunjberga V, Erzen M, Juschenko A, Serpa Hammes L, Podistov J, Costa S, Syrjänen S; NIS
Study Research Group; LAMS Study Research Group. Covariates of high-risk human
15
Molecular Oncology Research Center – Barretos Cancer Hospital
papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by
competing-risks regression models. Eur J Gynaecol Oncol. 2012; 33(1):5-14. IF: 0.474.
48. Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto Filho A, Derchain S, Kozachenko V,
Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M,
Grunjberga V, Erzen M, Juschenko A, Hammes LS, Podistov J, Costa S, Syrjänen S; NIS Study
Research Group; LAMS Study Research Group. Longitudinal outcomes of high-risk human
papillomavirus (HPV) infections as competing-risks events following cervical HPV test at
baseline visit in the NIS-LAMS cohort. Eur J Gynaecol Oncol. 2012; 33(4):341-52. IF: 0,474.
49. Tiburcio M, Costa SM, DE Fatima Duarte M, Schmitt FC, Longatto Filho A.
Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic
significance. Oncology Letters. 2012 Oct; 4(4):647-657. IF: 0.108.
50. Torrezan GT, Carneiro da Silva FC, Monteiro dos Santos EM, Rossi BM, Carraro DM,
Krepischi ACV. A novel SYBR-based duplex qPCR for the detection of gene dosage: detection
of an APC large deletion in a familial adenomatous polyposis patient with an unusual
phenotype. BMC Medical Genetics (Online). 2012 v. 13, p. 55-69. IF: 2.33.
51. Valadao M, Braggio D, Santos AF, Linhares E, Goncalves R, Romano S, Vilhena B, Small I,
de Oliveira, AT, Martinho, O, Reis, RM, Guimarães, DP, Ferreira, CG. Involvement of signaling
molecules in the prediction of response to imatinib treatment in metastatic GIST patients.
Journal of Surgical Research, 2012 Nov; 178(1):288-93. IF: 2.247.
52. Valentin MD, Da Silva FC, Santos EM, Da Silva SD, De Oliveira Ferreira F, Aguiar Junior S,
Gomy I, Vaccaro C, Redal MA, Della Valle A, Sarroca C, Rasmussen LJ, Carraro DM, Rossi BM.
Evaluation of MLH1 I219V polymorphism in unrelated South American individuals suspected
of having Lynch syndrome. Anticancer Research. 2012 Oct; 32(10):4347-51. IF: 1.65.
4.3) Publications in Brazilian Journals
1. Giacomazzi J, Aguiar E, Palmero EI, Schmidt AV, Skonieski G, Duarte-Filho D, Bock H,
Saraiva-Pereira ML, Ewald IP, Schuler-Faccini L, Camey SA, Caleffi M, Giugliani R, AshtonProlla P. Prevalence of ER -397 PvuII C/T, ER -351 XbaI A/G and PGR PROGINS
polymorphisms in Brazilian breast cancer unaffected women. Brazilian Journal of Medical
and Biological Research. 2012, Oct; 45(10):891-7. IF: 1.150.
16
Molecular Oncology Research Center – Barretos Cancer Hospital
2. Gurgel JD, Pereira CS, Fregnani JH, Ribeiro F de A. Method for removal of samples of ear
canal and tympanic membrane for histologic and immunhistochemical study. Braz J
Otorhinolaryngol. 2012 Feb; 78(1):37-42.
3. Liberman PHP, Goffi-Gomez MV, Schultz C, Lopes LF. Quais as frequências audiométricas
acometidas são responsáveis pela queixa auditiva nas disacusias por ototoxicidade após o
tratamento oncológico? Arquivos internacionais de otorrinolaringologia. 2012, 16, 26-31.
4. Matthes AG, Vieira R, Bailão A, Watanabe, A Kerr L, Saculatempo-Neto C, Uemura G,
Folgueira M. The role of tumor marking techniques in the treatment of locally advanced
breast cancer. Revista Brazileira de Mastologia. 2012, 21, 140-146.
5) Conferences and Congresses
5.1) Oral Communications
1. Arantes LMRB, Carvalho AC, Tajara EH, Carvalho AL, Bertollo EMG. Methylation profile of
CCNA1, p16, HIC1, TIMP3, MGMT and DCC genes in head and neck cancer. In: 16th
International Congress on Oral Pathology and Medicine and 20th Brazilian Congress of Oral
Medicine and Pathology, São Pedro, Brazil.
2. Bravo-Calderón DM, Lauand GA, Nonogaki S, Carvalho AL, Kovalski LP, Marana, AN.
Oliveira DT. BETA-2 adrenergic receptor expression in surgical margins of oral squamous cell
carcinoma. In: 16th International Congress on Oral Pathology and Medicine and 20th
Brazilian Congress of Oral Medicine and Pathology, São Pedro, Brazil
3. Campacci N, Fonseca TCB, Michelli RD, Haikel Junior R, Mauad EC, Reis RM, Carvalho AL,
Viana DV, Palmero EI. “Utilizaçao das unidades moveis e fixa de prevençao para
rastreamento populacional de familias com predisposiçao hereditaria de cancer de mama
e/ou colorretal”. III Encontro Científico do Hospital de Câncer de Barretos, 7 de January,
2012, Barretos, São Paulo, Brazil.
4. Carvalho AL, Mohssen A. Chiesa F, Kowalski LP. In the Era of Organ Preservation, What is
the Role of cT3 Laryngeal Surgery?. In: 8th International Conference on Head and Neck
Cancer, Toronto, Canada.
5. Carvalho AC, Maia DCC, Carvalho AL, Scapulatempo-Neto C, Vettore AL. MicroRNAs as
diagnostic markers for lymph node metastasis in OSCC. In: 16th International Congress on
Oral Pathology and Medicine and 20th Brazilian Congress of Oral Medicine and Pathology,
São Pedro, Brazil.
17
Molecular Oncology Research Center – Barretos Cancer Hospital
6. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira HCS. Assessing the
genotoxicity of urban air quality in Barretos during the sugarcane burning using Tradescantia
micronucleus (Trad-MCN) bioassay. In: 58 Congresso Brazileiro de Genética, 2012,
September de 2012, Foz do Iguaçu PR, Brazil.
7. de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J,
Oliveira P, Hespanhol V, Reis RM. Association between EGF +61 genetic polymorphisms and
non-small cell lung cancer increased risk in a Portuguese population: a case-control study.
Spring Meeting Oncology 2012. Évora, Portugal.
8. de Mello RA, Ferreira M, Pires FS, Costa C, Luis M, Cunha J, Oliveira P, Hespanhol V, Reis
RM. The role of genetic polymorphisms at the chromosomes 5p15.33, 6p12, 6p21, 6p21.3,
and 15q25 into non-small-cell lung cancer prognosis: a Portuguese prospective study. São
Paulo Advanced School of Comparative Oncology 30 Sept 30 – October 7, 2012. Águas de
São Pedro, SP, Brazil.
9. Hatakeyama M, Reis-Rosa L A, Abreu FB, Marchi FA, Spilborghs G, Carvalho AL, Nicolau U
R, Kowalski LP, Rogatto SR. Molecular Biomarkers of Chemo-Radiotherapy Response in
Oropharyngeal Squamous Cell Carcinomas. In: 8th International Conference on Head and
Neck Cancer, Toronto, Canada.
10. Laus AC, Santos SA, Laureano LAF, Huber J, Squire JA, Martelli L. Molecular Cytogenetic
Characterization of Supernumerary Marker Chromosomes. Encontro Paulista de
Citogenética, 2012, Ribeirão Preto, SP, Brazil.
11. Lopes LF- Papel do PET-CT nos TCG0 tumores de celulas germinativas na infancia. XIII
Congresso Brazileiro de Oncologia Pediatrica, 17-20 April, 2012, Natal, Brazil.
12. Marino ALF, Macedo T, Longatto Filho AF, Kerr LM, Vieira RAC, Evangelista AF, Silveira
HCS, Marques MMC. 58 Congresso Brazileiro de Genética-Prêmio Francisco Mauro Salzano,
September 11-14, 2012, Foz do Iguaçu, PR, Brazil.
13. Martinho O, Oliveira RJS, Miranda-Gonçalves V, Clara C, Almeida JR, Carvalho AL, Reis
RM. “Terapia molecular dirigia com cediranib, sunitinib e imatinib em modelos in vitro de
glioblastoma”. III Encontro Científico do Hospital de Câncer de Barretos, January7º, 2012,
Barretos, São Paulo, Brazil.
14. Martinho O, Pinto F, Granja S, Miranda-Gonçalves V, Moreira M, Ribeiro L, di Loreto C,
Rosner M, Longatto Filho A, Reis RM. Raf Kinase inhibitor (RKIP) depletion is associated with
cervical cancer aggressiveness. 10th ICCB/16th SBBC Meeting, July, 25-28, 2012, Rio de
18
Molecular Oncology Research Center – Barretos Cancer Hospital
Janeiro, Brazil.
15. Silva-Correia J, Pereira H, Yan L-P, Miranda-Gonçalves V, Oliveira A.L, Oliveira J.M, Reis
RM, Espregueira-Mendes JD, Reis RL. (2012). Novas matrizes de seda para Engenharia de
Tecidos do Menisco: A importância do controlo da neovascularização com Hidrogéis de
Goma Gelana Metacrilada – XXXII Congress of the Portuguese Society of Orthopaedics and
Traumatology, Vilamoura, Portugal.
5.2) Posters
1. Almeida MI, Nicoloso M, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Bondaruk J, Fabbri M,
Czerniak B, Lanza G, Reis RM, Zweidler-McKay P, Calin GA. Strand-Specific miR-28-5p and
miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. São Paulo Advanced School of
Comparative Oncology (ESPCA), September,30 to October 6, 2012, São Paulo, Brazil.
2. Ashton-Prolla P, Osorio CABT, Koehler-Santos P, Graudenz MS, Palmero EI, Fernandes G,
Michelli RD et al. Contribution of TP53 p.R337H mutation to breast cancer prevalence in
Brazil. In: 2012 ASCO Annual Meeting. June 1st to -5th, 2012, Chicago, USA.
3. Campacci N, Ramadan L, Caron TB, Fonseca TCB, Mauad EC, Michelli RD, Viana DV,
Palmero EI. Identification of at-risk families for hereditary breast cancer through a Brazilian
Cancer Prevention Network in a population-based sample. In: 4th International Symposium
on Hereditary Breast and Ovarian Cancer: From Theory to Practice. April, 25to27, 2012 ,
Montreal, Canada.
4. Campacci N, Ramadan L, Mauad EC, Michelli RD, Viana DV, de Oliveira JC, Lima MP, de
Lima JC, Andrade C, Palmero EI. Is there a place for oncogenetics inside the Prevention Unit?
In: 4th International Symposium on Hereditary Breast and Ovarian Cancer: From Theory to
Practice. April 25to27, Montreal, Canada.
5. Campacci N, de Lima JO, Ramadam L, Michelli RD, Viana DV, Reis RM, Rossi BM, Mauad
EC, Carvalho AL, Palmero EI. Identificação de famílias em risco para câncer de mama e
câncer colorretal hereditários em uma amostra de base populacional. IV Encontro Cientifico
do Hospital de Câncer de Barretos, December, 2012, Barretos, SP, Brazil.
6. Campanella NC, Scapulatempo-Neto C, de Oliveira A.T, Guimaraes DP, Reis RM. Study of
microsatellite instability and potential target genes in GISTs. VII Congresso Franco Brazileiro
de Oncologia, September, 20to22, 2012, Rio de Janeiro, Brazil.
19
Molecular Oncology Research Center – Barretos Cancer Hospital
7. Camparoto ML, Scapulatempo-Neto C, Squire JA. Evaluation of HER-2 IHC and FISH
Analysis in Breast Cancer at the Routine Pathology of the Barretos Cancer Hospital-SP, Brazil.
Encontro Paulista de Citogenética, April, 22 to 24 of 2012, Ribeirão Preto, Brazil.
8. Carloni AC, Oliveira RJS, Camparotto ML, Clara C, Squire JA, Reis RM. Estabelecimento e
Caracterização Citogenética e Molecular de Culturas Primárias de Gliomas – Ensaios
Preliminares. II Encontro Paulista de CitogenéticaApril, 22 to 24, 2012, Ribeirão Preto, Brazil.
9. Carvalho D, Bjerke L, Bax D, Chen L, Kozarewa I, Baker S, Grundy R, Ashworth A, Lord C,
Hargrave D, Reis RM, Jones C. Identification of novel fusion genes in paediatric high grade
glioma. 15th International Symposium on Pediatric Neuro-Oncology – ISPNO, June, 24to27,
2012, Toronto, Canada.
10. Carvalho AL, Agra IMG, Scapulatempo Neto C, Kovalski LP. Locally Recurrent Oral
Carcinomas Submitted to Salvage Surgery: Expression of EGFR and p16 and their Relation
with the Treatment Outcomes. In: 8th International Conference on Head and Neck Cancer,
Toronto, Canada.
11. Carvalho GB, Gonçalves Filho J, Lima SP, Mannarini L, Horst MA, Carvalho AC, Maia DCC,
Carlin V, Carvalho AL, Kowalski LP, Vettore AL. MicroRNAs Profiling in Salivary Rinse from
Patients with Head and Neck Squamous Cells Carcinoma. In: AACR Annual Meeting, Chicago,
USA.
12. Carvalho GB, Gonçalves Filho J, Lima SP, Carvalho AL, Mohssem A, Chiesa F, Patel SG,
Montero PH, Shuman AG, Shah JP, Kowalski LP. Results of Treatment of T4A Squamous Cell
Carcinoma of the Larynx. In: 8th International Conference on Head and Neck Cancer,
Toronto, Canada.
13. Carvalho GB, Gonçalves Filho J, Lima SP, Carvalho AL, Mohssen A, Chiesa F, Patel SG,
Shaah JP, Kowalski LP. Predictive Factors of Prolonged Hospital Stay in Patients Undergoing
Total Laryngectomy. In: 8th International Conference on Head and Neck Cancer, Toronto,
Canada.
14. Colaiacovo W, Guimaraes DP, Gilberto Fava, Aldenir Fresca, Liza Alvarenga, Thiago R. Da
Cunha, Emiliano D. Almodova. Self-Expanding Metal Stent (SEMS) for Malignant Colorectal
Obstruction (MCO). Gastrointestinal Endoscopy Vol. 75, Issue 4, Supplement, Page AB427,
DDW, May, 19to22, Chicago, USA.
15. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira HCS. Assessing
the genotoxicity of urban air quality in Barretos during the sugarcane burning using
20
Molecular Oncology Research Center – Barretos Cancer Hospital
Tradescantia micronucleus (Trad-MCN) bioassay. 58 Congresso Brazileiro de Genética, 2012,
September, 2012, Foz do Iguaçu PR, Brazil.
16. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira HCS. Assessing
the genotoxicity of urban air quality in Barretos during the sugarcane burning using
Tradescantia micronucleus (Trad-MCN) bioassay. IV Encontro Científico do Hospital de
Câncer de Barretos, December, 2012, Barretos, SP, Brazil.
17. de Mello RA, Ferreira F, Pires FS, Costa S, Luis M, Cunha J, Oliveira P, Hespanhol V, Reis
RM. The role of genetic polymorphisms in the chromosomes 5p15.33, 6p12, 6p21, 6p21.3,
and 15q25 into non-small-cell lung cancer prognosis: a Portuguese prospective study. São
Paulo Advanced School of Comparative Oncology (ESPCA), September 30th to October 6th,
2012, São Paulo, Brazil.
18. da Silva TR, de Oliveira JC, Rossi BM, Palmero EI. Identificação e caracterização de
pacientes em risco para câncer colorretal hereditário. IV Encontro Cientifico do Hospital de
Câncer de Barretos, December, 2012, Barretos, SP, Brazil.
19. de Lima JO, Campacci N, Ramadan L, Palmero EI. Utilização de um guia informativo para
avaliar o conhecimento em relação ao Câncer Hereditário. IV Encontro Cientifico do Hospital
de Câncer de Barretos, December 2012, Barretos, SP, Brazil.
20. dos Santos LC, Nogueira de Souza N, Scapulatempo-Neto c, Berardinelli G, dos Santos FP,
Lopes H, Silva MC, Jácome A, Oliveira J, Denadai M, Carvalho AL, Reis RM. Study of
Biomarkers Predictive of Response to Anti-EGFR Monoclonal Antibodies for Metastatic
Colorectal Cancer Patients: The experience of Barretos Cancer Hospital. Global Academic
Program Meeting, May 14th to16th 2012, Oslo, Norway.
21. Evangelista, AF; Xavier DJ; Sakamoto-Hojo ET; Donadi EA; Passos GAS; Marques MMC.
MicroRNAs from peripheral blood mononuclear cells can be used as biomarkers for
detection of preclinical fibrosarcoma. Hallmarks of Cancer, October 29 th to31st, San
Francisco-CA, USA.
22. Fernandes GC, Fonseca TCB, Michelli RAD, Mendes DRP, Escremin AP, Reis RM, Viana DV,
Mauad EC, Scapulatempo-Neto C, Palmero EI. Prevalence of positive breast cancer history
and triple negative breast cancer cases in women with and without BRCA germline
mutations. In: 58 Congresso Brazileiro de Genética, 2012, Foz do Iguaçu PR, Brazil.
23. Fernandes GC, Fonseca TCB, Michelli RD, de Paula DR, de Paula AE, Viana DV,
Scapulatempo-Neto C, Palmero EI. Triple Negative breast cancers and positive family history
21
Molecular Oncology Research Center – Barretos Cancer Hospital
are predictors of BRCA1 germline mutations. IV Encontro Cientifico do Hospital de Câncer de
Barretos, December 2012, Barretos, SP, Brazil.
24. Hennessey PT, Mydlarz WK, Wang H, Carvalho AL, Califano JA. Serum Biomarkers for
Detection of Head and Neck Squamous Cell Carcinoma. In: 8th International Conference on
Head and Neck Cancer, Toronto, Canada.
25. Horst MA, Carvalho AC, Maia DC, Pelarin MFA, Carvalho AL, Kowalski LP, Vettore AL.
MicroRNAs in salivary rinse as biomarkers for recurrence detection of head and neck
squamous cell carcinoma. In: 16th International Congress on Oral Pathology and Medicine
and 20th Brazilian Congress of Oral Medicine and Pathology, 2012, São Pedro. Scientific
Program, 2012.
26. Lacerda C, Campanella NC, Scapulatempo-Neto C, Wohnrath DR, Almodova E, Silva S,
Dias C, Oliveira AT, Guimaraes DP, Reis RM. Esophageal GIST: a case report. 11th OESO
World Congress on Diseases of the Oesophagus. September 01st to 04th, 2012, Como, Italy.
27. Lacerda C, Carloni AC, Scapulatempo-Neto C, Crema E, Rodrigues MA, de Oliveira AT,
Guimaraes DP, Reis RM. TP53 gene mutations in Squamous Cells Carcinoma of the
Esophagus Associated with Chagasic Megaesophagus. 11th OESO World Congress on
Diseases of the Oesophagus. September 01-04, 2012, Como, Italy.
28. Laus AC, Santos SA, Laureano LAF, Huber J, Squire JA, Martelli L. Molecular Cytogenetic
Characterization of Supernumerary Marker Chromosomes. Encontro Paulista de
Citogenética, 2012, Ribeirão Preto, SP, Brazil.
29. Laus AC, Macedo T, Carvalho AC, Scapulatempo Neto C, Carvalho AL, Palmero EI,
Marques MMC. MicroRNAs contribute to the chemoresistance of cisplatin and paclitaxel in
patients with head and neck squamous cell carcinoma. 3° Encontro Científico do Hospital de
Câncer de Barretos, 2012, Barretos, SP, Brazil.
30. Lopes LF, Gaiolla RD, Niero-Melo L, Lorand-Metze I, Velloso EDRP, Tanizawa RSS,
Campanaro CM, Souto EX, Zerbini MC, Luporini SM, Lee ML, Magalhães IMQS, Pinheiro VR,
Seber A, Vidal DO, Santos VR. The Brazilian Cooperative Group on Pediatric Myelodysplastic
Syndrome (GCB-SMD-PED). Is it relevant to improve educational approach and correct
diagnosis? VI International Symposium on Myelodysplastic Syndromes and Bone Marrow
Failures in Childhood. November 7th to9th, 2012, Prague, Czech Republic.
31. Macedo T; Evangelista AF; Kerr LM; Guerreiro da Silva IDC; Vieira RAC; Marques MM
Differential expression of circulating microRNAs in serum of breast cancer patients using
22
Molecular Oncology Research Center – Barretos Cancer Hospital
quantitative reverse transcription (qRT-PCR). VII Congresso Franco Brazileiro de Oncologia,
September, 20th to 22nd, Rio de Janeiro, Brazil.
32. Macedo T; Laus C; De Carvalho AC; Queiroz Junior AF; Kerr LM; Marino ALF; Rodriges AL;
Guerreiro da Silva IDC; Vieira RAC; Marques MMC. Circulating microRNAs are differentially
expressed in the serum of patients with breast câncer. 3° Encontro Científico do Hospital de
Câncer de Barretos, 2012, Barretos, SP, Brazil.
33. Marino ALF; Macedo T; Queiroz Junior AF; Kerr LM; Vieira RAC; Evangelista AF; Silveira
HCS; Marques MMC. Analysis of microRNA expression comparing matched frozen and
formalin-fixed paraffin- embedded human breast cancer samples. 3° Encontro Científico do
Hospital de Câncer de Barretos, 2012, Barretos, SP, Brazil.
34. Marino ALF; Macedo T; Queiroz Junior AF; Kerr LM; Vieira RAC; Evangelista AF; Silveira
HCS; Marques MMC. Analysis of microRNA expression usisng tissue frozen and formalinfixed paraffin embedded from breast cancer samples. MicroRNA 2012 International
Symposium, 2012, São Paulo, Brazil.
35. Marino ALF; Evangelista AF; Longatto Filho A; Kerr LM; Vieira RAC; Macedo T; Silveira
HCS; Marques MMC. Differential expression profile of microRNAs during human breast
cancer progression. 58° Congresso Brazileiro de Genetica, September 11th to14th, Foz do
Iguaçu, PR, Brazil.
36. Marino ALF; Evangelista AF; Longatto Filho A; Kerr LM; Vieira RAC; Macedo T; Silveira
HCS; Marques MMC. Differential expression profile of microRNAs during human breast
cancer progression. VII Congresso Franco Brazileiro de Oncologia, September, 20th to 22nd,
Rio de Janeiro, Brazil.
37. Marino ALF; Evangelista AF; Longatto Filho A; Kerr LM; Vieira RAC; Macedo T; Silveira
HCS; Marques MMC. Differential expression profile of paraffin embedded microRNAs during
human breast cancer progression. Hallmarks of Cancer, October 29th to 31st, San FranciscoCA, USA.
38. Martinho O, Miranda-Gonçalves V, Reis RM. Identification of novel potential predictive
targets to anti-angiogenic therapy response in glioblastomas. 10th ICCB/16th SBBC Meeting,
July 25th to 28th, 2012, Rio de Janeiro, Brazil.
39. Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R,
Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S,
Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Comprehensive investigation of the
23
Molecular Oncology Research Center – Barretos Cancer Hospital
8q24 region and multiple myeloma risk in the context of the IMMENSE Consortium. 17th
EHA congress, 14th to 17th June 2012, Amsterdam, Holland.
40. Mendes DRP, Fernandes GC, Escremin AP, Michelli RAD, Andrade CE, Oliveira JC, Mauad
EC, Reis RM, Viana DV, Palmero EI. High frequency of a BRCA1 founder mutation in a nonJewish population affected by bilateral breast cancer. In: 58 Congresso Brazileiro de
Genética, 2012, Foz do Iguaçu PR, Brazil.
41. Miranda-Gonçalves V, Honavar M, Pinheiro C, Reis RM, Baltazar F. MCT1 plasma
membrane expression is associated to hypoxic regions in glioblastomas. EACR22, 7 to 10 July
2012, Barcelona, Spain.
42. Motta VM, Camparoto ML, Ferreira MCS, Gonçalves IZ, Paton, EJA, Castro NS , Colli GF,
Squire JA. Retrospective cytogenetic approach on patients with hematological malignancies
at Barretos Cancer Hospital. Encontro Paulista de Citogenética, 22nd to 24th, April, 2012,
Ribeirão Preto, SP, Brazil.
43. Nandhabalan M, Bjerke L, Bax DA, Carvalho D, Bajrami I, Ashworth A, Lord C, Reis RM,
Workman P, Jones C. H3F3A mutations in paediatric glioblastoma regulate a self-renewal
gene signature. 15th International Symposium on Pediatric Neuro-Oncology – ISPNO, June,
24th to 27th, 2012, Toronto, Canada.
44. Oliveira RS, Martinho O, Clara C, Almeida JR, Reis RM. Establishment of primary
glioblastoma cell cultures for new treatment approaches screening. 10th ICCB/16th SBBC
Meeting, July 25th to 28th, 2012, Rio de Jananeiro, Brazil.
45. Palmero EI, Michelli RD, Rossi BM, de Oliveira JC, Andrade C, Lima MP, de Lima JC,
Mauad E, Reis RM, Carvalho AL, Viana DV. Free of cost genetic counseling of at-risk for
hereditary breast and ovarian cancer families from Brazilian Federal Health Insurance: A
pioneer institutional experience. In: 4th International Symposium on Hereditary Breast and
Ovarian Cancer: From Theory to Practice. April 25 th to -27 th, 2012, Montreal, Canada.
46. Pinto F, Martinho O, Moniz S, Jones C, Lopes JM, Honavar M, Pires MM, Jordan P, Reis
RM. Protein kinase WNK2 was correlated with poor outcome and malignant behavior in
glioma cell lines. EACR22, 7 to 10 July 2012, Barcelona, Spain.
47. Pinto F, Andrade RP, Reis RM. T-box transcription factor Brachyury as a suppressor gene
in gliomas? São Paulo Advanced School of Comparative Oncology (ESPCA), September30th
to 6th October 2012, São Paulo, Brazil.
24
Molecular Oncology Research Center – Barretos Cancer Hospital
48. Rossi BM, Michelli RD, Viana DV, de Oliveira JC, Andrade C, Reis RM, de Paula DR,
Fernandes G, Carvalho AL, Palmero EI. Free of cost genetic counseling and testing of at-risk
for hereditary cancer families from Brazilian Federal Health Insurance: A pioneer
institutional experience. In: Society of Surgical Oncology’s 65th Annual Cancer Symposium.
March 21st-24th, Orlando, EUA.
49. Silva AG, Maschietto M, Vidal DO, Peliçario LM, Velloso EDRP, Lopes LF, Krepischi AC,
Rosenberg C. Array-CGH as an adjuvant tool in cytogenetic diagnosis of myeloid neoplasms.
VI International Symposium on Myelodysplastic Syndromes and Bone Marrow Failures in
Childhood. November 7th to 9th, 2012, Prague, Szech Republic.
50. Silva DS, Viana-Pereira M, Stavale JN, Malheiro S, Almeida GS, Clara C, Jones C, Reis RM.
Study of MSI and novel target genes associated with MSI phenotype in medulloblastomas.
15th International Symposium on Pediatric Neuro-Oncology – ISPNO, 24th to 27th, June
2012, Toronto, Canada.
51. Silveira HCS, Schmidt-Carrijo M, Zanardo-Oliveira C, Seidel EH, Villegas C, Scapulatempo
C, Longatto Filho A, Carvalho AL, Reis RM, Saldiva PH. Análise da Poluição do Ar gerada pela
queima da palha da cana-de-açúcar e suas relações com a mutagênese humana. III Encontro
Cientifico do Hospital de Câncer de Barretos, 6th to 7th, January, 2012, Barretos, SP, Brazil.
52. Silveira HCS, Schmidt-Carrijo M, Zanardo-Oliveira C, Seidel EH, Villegas C, Scapulatempo
C, Longatto Filho A, Carvalho AL, Reis RM, Saldiva PH. Evaluation of genotoxic effects of
sugarcane workers using micronucleus assay. In: 58 Congresso Brazileiro de Genética, 2012,
Foz do Iguaçu PR, Brazil.
53. Silveira HCS, Schmidt-Carrijo M, Zanardo-Oliveira C, Seidel EH, Villegas C, Scapulatempo
C, Longatto Filho A, Carvalho AL, Reis RM, Saldiva PH. Evaluation of genotoxic effects of
sugarcane workers using micronucleus assay. IV Encontro Científico do Hospital de Câncer
de Barretos, December 2012, Barretos, SP, Brazil.
54. Velloso EDRP, Chauffaille ML, Peliçario LM, Tanizawa RSS, Toledo SRC, Gaiolla RD, Vidal
DO, Lopes LF. Cytogenetics from the Brazilian MDS Pediatric Group (GCB-SMD-PED). VI
International Symposium on Myelodysplastic Syndromes and Bone Marrow Failures in
Childhood. November 7th to 9th 2012, Prague, Szech Republic
55. Viana-Pereira M, Pereira MS, Burford A, Jury A, Popov S, Perryman L, Bax DA, Forshew T,
Sheer D, Pimentel J, Pires M, Reis RM, Jones C. Molecular determinants of efficacy of MET
25
Molecular Oncology Research Center – Barretos Cancer Hospital
receptor inhibition in paediatric glioblastoma. 15th International Symposium on Pediatric
Neuro-Oncology – ISPNO, 24th to 27th, June 2012, Toronto, Canada.
56. Viana-Pereira M, Pereira MS, Burford A, Jury A, Popov S, Perryman L, Bax DA, Forshew T,
Tatevossian R, Sheer D, Pimentel J, Pires MM, Reis RM, Jones C. Molecular study and
inhibition of MET receptor in paediatric high-grade glioma. São Paulo Advanced School of
Comparative Oncology (ESPCA), September 30th -6th October 2012, São Paulo, Brazil.
57. Vieira de Castro J, Martinho O, Miranda-Gonçalves V, Baltazar F, Reis RM. Dissecting the
role of glioblastoma cell metabolism in response to imatinib. Porto Cancer Meeting, 19th
20th April 2012, Porto, Portugal.
58. Vieira de Castro J, Martinho O, Miranda-Gonçalves V, Baltazar F, Reis RM. Role of
glioblastoma cell metabolism in response to anti-RTK therapy. EACR22, 7th to 10th July 2012,
Barcelona, Spain.
59. Vidal DO, Silva AG, Marchietto M, Vieira H, Lopes LF, Brentani H, Rosenberg C, Krepischi
AC. Microarray-Based DNA methylation analysis in pediatric myelodysplastic syndrome and
juvenile myelomonocytic leukemia. VI International Symposium on Myelodysplastic
Syndromes and Bone Marrow Failures in Childhood. November 7th 9th 2012, Szech Republic.
60. Yamane L, Scapulatempo Neto C, Alvarenga L, Oliveira C, Berardinelli G, Almodova E,
Cunha TR, Colaiacovo W, Melani A, Freganini JH, Reis RM, Guimarães DP. Morphological and
molecular characterization of colorectal lesions detected and removed by colonoscopy.
Global Academic Program Meeting, May 14 th16th 2012, Oslo, Norway
61. Yamane L, Scapulatempo Neto C, Alvarenga L, Zanardo, C, Berardinelli G, Almodova E,
Cunha TR, Colaiacovo W, Melani A, Freganini JH, Reis RM, Guimarães DP. Study of the
morphologic and molecular profile of colorectal lesions detected and removed by
colonoscopy. VII Congresso Franco Brazileiro de Oncologia, September, 20th to 22nd, Rio de
January, Brazil.
6) Science Communication to general public
-Silveira HCS: Fumaça gerada pela queima do diesel causa câncer, alerta OMS. Gazeta do
Povo,Curitiba,16deJuly2012.
(http://www.gazetadopovo.com.br/vidaecidadania/conteudo.phtml?tl=1&id=1274792&tit=
Fumaca-gerada-pela-queima-do-diesel-causa-cancer-alerta-OMS).
26
Molecular Oncology Research Center – Barretos Cancer Hospital
-Reis RM, Carvalho AL: Revista Hospital do Futuro, HdF Nº15, Portugal – O Hospital de
Câncer de Barretos.
7) Supervision of PhD, Master and Trainee Fellows
7.1) PhD Thesis
1. Adriana Lorenzi. “Valor do teste careHPV de captura híbrida em Unidade Móvel no
rastreio do câncer cervical em áreas rurais e remotas”. HCB (Supervisor - Longatto Filho, A.).
2011 to present.
2. Aline Nazareth de Paiva Paixão Becker. “Avaliação da via MAPK na oncogênese dos
astrocitomas pilocíticos”. HCB (Supervisor – Reis RM; Co-supervisor – Scapulatempo-Neto C).
2012 to present.
3. Carolina Dias Carlos. “Estudo de Biomarcadores Terapêuticos em pacientes com Câncer
de Pulmão do Hospital de Câncer de Barretos”. HCB (Supervisor – Reis RM; Co-supervisor –
Scapulatempo-Neto C; Co-supervisor – Viana L). 2012 to present.
4. Filipe Pinto, projeto “Learning from the embryo: Understanding early embryonic T gene Brachyury - impact in human tumorigenesis” ICVS, Universidade do Minho (Supervisor – Reis
RM). 2011 to present.
5. Herlander Jose Resende Marques. Prevalência de vírus Herpes nos Linfomas Foliculares
Influência dos polimorfismos dos sistemas apresentadores de antigénio na infecção crónica.
ICVS, Universidade do Minho. (Supervisor - Longatto Filho A). 2008 to present.
6. Julieta Alexandra Pereira Afonso. The Biology of Lymphatic Spread of Urothelial Bladder
Cancer. ICVS, Universidade do Minho. (Supervisor - Longatto Filho A). 2008 to present.
7. Junea Caris de Oliveira. “Correlação genotipo-fenotipo em pacientes portadores de
Polipose Adenomatosa Familial”. HCB (Supervisor – Rossi BM; Co-Supervisor Palmero EI).
2012 to present.
8. Leonado Gabeira Secco. “Fatores Prognósticos em Carcinoma Bem Diferenciado da
Tireóide”. FMUSP (Supervisor – Carvalho AL). 2005 to present.
9. Maria Inês Almeida, projeto “Molecular determinants of human susceptibility to solid
tumors and therapy response: A microRNA Hub” ICVS Universidade do Minho/MD Anderson,
Houston, USA (Supervisor – Reis RM). 2009 to 2012.
27
Molecular Oncology Research Center – Barretos Cancer Hospital
10. Maria Teresa Roncaglia, projeto “O valor da captura híbrida para HPV no seguimento de
pacientes com neoplasia intra-epitelial de alto grau submetidas à conização do colo uterino
por cirurgia de alta freqüência”. FMUSP (Supervisor – Longatto Filho A). 2010 to present.
11. Roberta Targa Stramandinoli, projeto “Avaliação da interface osso/implante em
mandíbula de miniporcos irradiados e o uso de biomateriais na osseointegração”. FMUSP
(Supervisor – Carvalho AL). 2010 to present.
12. Sandra Fátima Fernandes Martins. ICVS, Universidade do Minho. (Supervisor - Longatto
Filho L). 2008 to present.
13. Thiago Buosi Silva. “Desenvolvimento e validação de nomogramas para estimar os
riscos de câncer de próstata e de câncer de próstata de baixo e alto grau de malignidade”.
FMUSP (Supervisor – Carvalho AL). 2010 to present.
14. Renato José da Silva Oliveira. “Identificação de novos biomarcadores preditivos da
resposta à terapia anti-EGFR em tumores sólidos. HCB (Supervisor – Reis RM; Co-supervisor
– Carvalho AL). 2011 to present.
7.2) Master Thesis
1. Adriana Cruvinel, projeto “Caracterização Citogenética e Molecular de Linhagens
Primárias de Gliomas”. HCB (Supervisor - Reis RM). 2011 to present.
2. Adriano Jander Ferreira, projeto: “Catalogação dos pacientes com diagnostico de
Sarcoma de Ewing tratados no Hospital de Câncer de Barretos”. HCB (Supervisor - Lopes LF).
2011 to present
3. Aline Caroline Camargo Mendonça, projeto: “Análise das características clínico epidemiológicas e de sobrevida dos casos de câncer pediátrico da Fundação Pio XII Hospital de Câncer de Barretos período de 2000 à 2011, HCB (Supervisor - Lopes LF). 2011 to
present.
4. Ana Laura Bordinhão Rodrigues, “Avaliação da expressão de microRNAs em linhagens
celulares de carcinoma mamário humano expostas a ação do fármaco Cediranib”. HCB
(Supervisor - Marques MMC). 2011 to present.
5. Augusto Ludvik Filip Marino, projeto “Análise do perfil de expressão diferencial de
microRNAs em carcinomas mamários por microarrays”. HCB (Supervisor - Marques MMC).
2011 to present.
28
Molecular Oncology Research Center – Barretos Cancer Hospital
6. Carla Aparecida Pinheiro, projeto “Estudo de Instabilidade Cromossômica e Correlação
com as Características Clinicopatológicas em Condrossarcomas”. HCB (Supervisor Camparoto ML) 2012 to present.
7. Croider Franco Lacerda, projeto “Estudo do gene supressor tumoral, TP53, no carcinoma
de células escamosas do esôfago associado ao megaesôfago chagásico” HCB (Supervisor Reis RM; Co-Supervisor Guimaraes DP). 2011 to present.
8. Emilze Mafra de Lima. Saúde oral como fator de risco para neutropenia febril pósquimioterapia em pacientes com neoplasias hematológicas. HCB. (Supervisor - Fregnani JH).
2011 to present.
9. Fernando Luís Visoni Poliseli – “Avaliação do número de cópias do gene TOP2A e da
expressão da sua proteína em leiomiossarcomas uterinos”. Hospital A.C. Camargo
(Supervisor - Fregnani JH) 2010-2012.
10. Flávia Coltri Eguchi, projeto “Avaliação da superexpressão das proteínas TMPRSS2 e
ERG e a fusão gênica TMPRSS2:ERG em portadores de câncer prostático”. HCB. (Supervisor Campos, SGP). 2011 to present.
11. Juliana Levy Daher, “Aspectos funcionais e emocionais da deglutição e fonação no
paciente com câncer de cabeça e pescoço pré e pós tratamento oncológico Hospital de
Câncer de Barretos” (HCB Supervisor - Carvalho AL). 2011 to present.
12. Letícia Rodrigues Cardoso. “Síndrome de Dor Miofascial em pacientes portadores de
câncer de cabeça e pescoço” HCB (Supervisor - Carvalho AL). 2011 to present.
13. Leticia dos Santos Yamane. “Estudo mutacional dos oncogeneses KRAS e BRAF nas
lesões do cólon e reto”. HCB (Supervisor – Guimaraes DG; Co-Supervisor Reis RM). 2011 to
present.
14. Luiz Cesar Záccaro da Silva. “Análise crítica da discrepância entre achados
histopatológicos da biópsia prostática realizada em centros não oncológicos e sua revisão
em um centro oncológico”. HCB (Supervisor - Scapualtempo-Neto, C). 2011 to present.
15. Maira DeGiovani Stein, projeto “Desempenho diagnóstico da citologia manual versus a
citologia assistida por computador usando BD FocalPoint GS Imaging system em material
preparado em sistema BD SurePath de base líquida”. HCB (Supervisor - Longatto Filho A).
2011 to present.
29
Molecular Oncology Research Center – Barretos Cancer Hospital
16. Natalia Campacci, projeto “Rastreamento populacional de famílias com predisposição
hereditária de câncer de mama e/ou câncer colorretal”. HCB (Supervisor - Palmero EI) 2011
to present.
17. Nathália Cristina Campanella. “Estudo da instabilidade de microssatélite e potenciais
genes alvos em GISTs”. HCB (Supervisor - Reis RM) 2012 to present.
18. Paulo Henrique Zanvettor – “Estudo de fatores prognósticos clínicos e biomoleculares
de pacientes portadores de câncer de vulva submetidos a tratamento cirúrgico”.
Universidade de São Paulo. (Supervisor - Fregnani JH). 2010-2012
19. Taciane Macedo, “Estudo funcional de microRNAs associados ao processo de metástase
em linhagens celulares de carcinoma mamário humano”. HCB (Supervisor - Marques, MMC)
2012 to present.
7.3) Trainee Fellows
1. André de Lima Mota, projeto Avaliação da expressão de VEGF e do seu receptor VEGFR1/Flt-1 e VEGFR-2/Flk-1 em linhagens celulares de carcinoma mamário humano expostas a
ação do fármaco Cediranib”. HCB (Supervisor - Marques MMC). 2012 to present.
2. Fernanda de Paula Cury. Análise do potencial risco de câncer na exposição dos
trabalhadores da construção civil a agentes carcinogênicos. HCB (Supervisor – Silveira HC).
2012 to present.
3. Graziela Sartori, projeto “Caracterização molecular em melanomas acrolentiginosos e das
mucosas.” HCB (Supervisor – Vazquez VL). 2012 to present.
4. Isabela de Carvalho, Projeto “Padronização e estabelecimento do Cultivo de amostras
tumorais de sarcomas humanos e análise da amplificação do centrossomo”. - HCB, HCB.
(Supervisor - Camparoto ML). 2011 to 2012.
5. Juliana Oliveira de Lima, Projeto “Rastreamento populacional de famílias com
predisposição hereditária de câncer de mama e/ou câncer colorretal”. HCB. (SupervisorPalmero EI). 2012 to present.
6. Lamis Ramadan. Desenvolvimento de estrategias educativas para famílias com
predisposição hereditária ao câncer de mama e/ou câncer colorretal. HCB. (Supervisor Palmero EI). 2012 to present.
7. Talitha Cezareti Blau Fonseca, projeto “Identificação de mulheres em risco para câncer
de mama hereditário por mutação nos genes BRCA1 e BRCA2: contribuição dos dados
30
Molecular Oncology Research Center – Barretos Cancer Hospital
patológicos, história familiar e modificadores genéticos do risco de câncer”. HCB (Supervisor
- Palmero EI). 2011 to present.
8) Prizes
1. Best oral communication at RNA Meeting, January 26th to 27th, 2012, Lisbon, Portugal.
Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Zhang X, Vannini I, Fanini F,
Fabbri M, Lanza G, Reis RM, Zweidler-McKay PA, Calin GA. Biological Effects of miR-28-5p
and miR-28-3p in colorectal cancer.
2. Best Poster on IV Scientific Meeting at Barretos Cancer Hospital. December 2012,
Barretos, SP, Brazil. Fernandes GC, Fonseca TCB, Michelli RD, de Paula DR, de Paula AE,
Viana DV, Scapulatempo-Neto C, Palmero EI. Triple Negative breast cancers and positive
family history are predictors of BRCA1 germline mutations.
3. Honor Mention Award to the Best communication in Human Cytogenetics at the 2nd
Paulista Cytogenetics Meeting para, Ribeirão Preto, São Paulo, Brazil – 2012. Laus AC, Santos
SA, Laureano LAF, Huber J, Squire JA, Martelli L. Molecular Cytogenetic Characterization of
Supernumerary Marker Chromosomes.
4. Honor Mention Award at IV Scientific Meeting of Barretos Cancer, December 2012,
Barretos, SP, Brazil. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira
HCS. Assessing the genotoxicity of urban air quality in Barretos during the sugarcane burning
using Tradescantia micronucleus (Trad-MCN) bioassay.
5. Honor Mention Award to the student Cury FP because of the Best Initiation for Research
Fellows job at 58th National Genetic Congress, on September at Foz do Iguaçu. Assessing
the genotoxicity of urban air quality in Barretos during the sugarcane burning using
Tradescantia micronucleus (Trad-MCN) bioassay. Cury FP, Schmidt-Carrijo M, Villegas CM,
Seidel EH, Saldiva PH, Silveira HCS.
6. Francisco Mauro Salzano Prize to the Best Human and Medicine Genetics work at the
58th National Genetic Congress in September, Foz do Iguaçu, Brazil. Marino ALF,
Evangelista AF, Longatto AF, Kerr LM, Vieira RAC, Macedo T, Silveira HCS, Marques MMC.
Differential expression profile of microRNAs during human breast cancer progression.
7. Travel awarded at 10th ICCB/16th SBBC Meeting. Rio de Janeiro, Brazil. Martinho O,
Pinto F, Granja S, Miranda-Gonçalves V, Moreira M, Ribeiro L, di Loreto C, Rosner M,
31
Molecular Oncology Research Center – Barretos Cancer Hospital
Longatto Filho A, Reis RM. Raf Kinase inhibitor (RKIP) depletion is associated with cervical
cancer
8. VII Prêmio Saúde Abril 2012– Women and Men Health. Using mobile and fixed units with
hereditary predisposition to breast cancer families. Campacci N, Viana DV, Michelli RD,
Mauad EC, Haikel Junior R, Reis RM, Carvalho AL e Palmero EI.
9) Participation in International Networks
1. Carvalho AL, Reis RM - International Cancer Genome Consortium. 2012 to present.
2. Carvalho AL, Marques MMC, Reis RM, Scapulatempo-Neto C - US-Latin American Cancer
Research Network (USLACRN). 2010 to present.
3. Carvalho AL, Mauad EC - WIN - World Innovative Networking, 2010 to present.
4. Carvalho AL - INTERCHANGE – Head and Neck Study Group (IARC), 2010 to present.
5. Mauad EC, Carvalho AL, Reis RM, Scapulatempo-Neto C – GAP – Global Academic
Program – Sister Institution Network (MDANderson). 2011 to present.
6. Reis RM - IMMEnSE (International Multiple Myeloma rESEarch) consortium – 2010 to
present.
7. Reis RM - Société Internationale d'Oncologie Pédiatrique (SIOP) - Brain Tumour
Committee- High Grade Glioma Working Group. 2010 to present.
10) Participation in National Networks
1. Carvalho AL - Scapulatempo-Neto C – GENCAPO – Projeto de Genoma Cabeça e Pescoço
Brazileiro, 2010 to present.
2. Palmero EI - Rede Brazileira de Câncer Familiar, 2010 to present.
3. Silveira HC – INAIRA - Instituto Nacional de Análise Integrada do Risco Ambiental (INCT),
2011 to present.
11) Organization of Conferences and Meetings
1. Lopes LF. 1a Jornada Interdisciplinar Regional em Oncologia Pediátrica, 2012.
2. Lopes LF. Simpósio Internacional de Oncologia Pediátrica, 2012.
32
Molecular Oncology Research Center – Barretos Cancer Hospital
3. Rossi BM. Especialização em Coloproctologia – Câncer Colorretal – Hospital Sírio Libanês –
Coordenador do Curso 2012.
4. Silveira HCS, Carvalho AL. Catâneo C. 2˚ Workshop de Meio Ambiente do Hospital de
Câncer de Barretos, 2012.
12) Lectures Executed / Seminars at Conferences and Meetings
1. Carvalho AL. Personalized Medicine for Head and Neck Cancer: Are we there yet? Global
Academic Program Meeting, May 14th to 16th 2012, Oslo, Norway.
2. Carvalho AL. Head and Neck Cancer Care in Brazil. 8th International Conference on Head
and Neck Cancer, Toronto, Canada.
3. Carvalho AL. Formação do Cirurgião de Cabeça e Pescoço - Pesquisa. I Jornada Acadêmica
Sul Brazileira de cirurgia de Cabeça e Pescoço. Florianópolis, Brazil.
4. Carvalho AL. Implicações da Infecção por HPV no Manejo do CEC da Orofaringe. 1o
Congresso Ítalo-Brazileiro de Cirurgia de Cabeça e Pescoço. Rio de Janeiro, Brazil.
5. Carvalho AL. Carcinoma Avançado de Laringe, Preservação da Laringe com Radioterapia +
Quimioterapia - Critérios Utilizados para Selecionar os Melhores Candidatos. Jornada NorteNordeste de Cirurgia de Cabeça e Pescoço. Salvador, Brazil.
6. Carvalho AL. Porque a Mortalidade por Câncer de Laringe Avançado Aumentou nas
Últimas Décadas? Análise Crítica da Literatura. 2012. Jornada Norte-Nordeste de Cirurgia de
Cabeça e Pescoço. Salvador, Brazil.
7. Marques MMC. Biologia Tumoral: O que realmente está ao nosso alcance? IV Simpósio de
Mastologia, Oncologia, e Imagenologia Mamária de São José do Rio Preto, October 2012,
Universidade Paulista, São José do Rio Preto, SP, Brazil.
8. Reis RM. Câncer Gástrico Familiar. I Congresso Pan-Americano de Câncer Gástrico.
September 6-8 2012, Porto Alegre, Brazil.
9. Reis RM. Microsatellite Instabiltiy in Brain Tumors. Simpósio Internacional de Oncologia
Pediátrica, 25-26 de March, 2012, Barretos, SP, Brazil.
10. Rossi BM. Cirurgias pélvicas ampliadas – XVI Congresso Paraguaio de Cirurgia, Assunción,
Paraguay - Sep/2012.
11. Rossi BM. Discussão de casos clínicos: conselho dos mestres – XVI Congresso Paraguaio
de Cirurgia, Assuncion, Paraguay-Sep/2012.
33
Molecular Oncology Research Center – Barretos Cancer Hospital
12. Rossi BM. Tratamento da carcinomatose peritoneal – XVI Congresso Paraguaio de
Cirurgia, Assuncion, Paraguay-Sep/2012.
13. Rossi BM. Modelo de registro de cancer hereditário – XVI Congresso Paraguaio de
Cirurgia, Assuncion, Paraguay-Sep/2012.
14. Rossi BM. Câncer colorretal Hereditário – XVI Congresso Paraguaio de Cirurgia,
Assuncion, Paraguay-Sep/2012.
15. Rossi BM. Síndromes de polipose intestinal – Simpósio Internacional Endosur, Santiago,
Chile-Aug/2012.
16. Rossi BM. Síndrome de Lynch – Simpósio Internacional Endosur, Santiago, Chile Aug/2012.
17. Rossi BM. Câncer colorretal hereditário – I Congresso Internacional de Biologia
Molecular, Lima, Peru Nov/2012.
18. Rossi BM. Câncer colorretal hereditário – Sao Paulo Advanced School of Comparative
Oncology, São Paulo - Oct/2012.
19. Rossi BM. Organização do Meeting Internacional de 2015 em São Paulo – InSIGHT
Council Meeting, London, England – Dec./2012.
20. Rossi BM. Diagnóstico das síndromes hereditárias: FAP, MAP, síndrome de Lynch e
síndrome X – Especialização em Coloproctologia – Câncer Colorretal – Hospital Sírio Libanês,
São Paulo – Sep/2012.
21. Rossi BM. Manejo dos pacientes com síndrome de Lynch e síndrome X – Especialização
em Coloproctologia – Câncer Colorretal – Hospital Sírio Libanês, São Paulo – Sep/2012.
22. Rossi BM. Carcinogênese colorretal – Especialização em Coloproctologia – Câncer
Colorretal – Hospital Sírio Libanês, São Paulo – Mar/2012.
23. Silveira HC. Meio Ambiente, Agrotóxicos e Câncer. 1º Seminario sobre produção
orgânica. June 29th 2012, Câmara Municipal de Barretos, Barretos, SP, Brazil.
24. Silveira HC. Análise da queima da palha de cana-de-açúcar e suas relações com a
mutagenese humana. 01st November, 2012, Instituto Federal de Educação, Ciencia e
Tecnologia de São Paulo - Campus Barretos, SP, Brazil.
25. Silveira HC. Meio Ambiente e suas relações com o câncer, November29th, 2012,
Instituto Federal de Educação, Ciencia e Tecnologia de São Paulo - Campus Barretos, SP,
Brazil.
34
Molecular Oncology Research Center – Barretos Cancer Hospital
Vidal DO. Biologia molecular e genômica de tumores pediátricos. I Encontro Capixaba de
Biomedicina
26. Vidal DO. Biologia molecular e genômica de tumores pediátricos. I Encontro Capixaba de
Biomedicina: “Desafios e Perspectivas”, November 21st-23rd 2012, Vitória, ES, Brazil.
13) Funding
13.1) Governmental Agencies
1. Análise de metilação em câncer de cabeça e pescoço
Funding Agency: FAPESP
Duration: 2010-2013
PI: Eloiza Tajara, Members: André Lopes Carvalho, Matias MelenDec.
2. Avaliação do papel de microRNAs diferencialmente expressos no controle de invasão e
metástase do câncer de mama.
Funding Agency: FAPESP
Duration: 2011-2013
PI: Marques MMC.
3. Avaliação da superexpressão das proteínas TMPRSS2 e ERG e a fusão gênica
TMPRSS2:ERG em portadores de câncer prostático .
Funding Agency: CNPq Universal
Duration: 2010-2012
PI: Silvana de Campos; Members: Longatto Filho A, Scapulatempo C.
4. “Identificaçao de mulheres em risco para cancer de mama hereditario: contribuiçao dos
dados anatomo-patologicos, historia familiar e polimorfismos geneticos para o
desenvolvimento do cancer de mama”.
Funding Agency: CNPq Universal
Duration: 2010-2012
PI: Edenir I Palmero
5. “Chamada CNPq Nº 014/2011- Caracterização da instabilidade genômica em
glioblastomas: identificação e elucidação de novas vias moleculares em tumores e culturas
primárias”.
Funding Agency: CNPq Universal
35
Molecular Oncology Research Center – Barretos Cancer Hospital
Duration: 2012-2013
PI: Reis RM; Members: Lucas Bidinotto, Adriana Curvini
6. “Fatores Preditivos de alterações citoarquiteturais induzidas pelo HPV após tratamento
cirúrgico de neoplasias intra-epiteliais do colo uterino”.
Funding Agency: FAPESP
Duration: 2010-2012
PI: Fregnani JH; Members: Ismael Silva
7. Implantação do Centro de Pesquisa Translacional em Oncologia - Edital FINEP - CT-INFRA
- 02/2010.
Funding Agency: FINEP
Duration: 2010-2012
PI: Carvalho AL; Reis RM
8. Instituto Nacional de Ciência E Tecnologia para o estudo de papilomaviroses humanas.
Funding Agency: CNPq - Auxílio financeiro / FAPESP
Duration: 2009 – 2013
PI: Luisa Lina Villa, Member: Longatto Filho A
9. Prefeitura Municipal de Barretos (secretária de Meio Ambiente e Educação) (4.000,00)
Apoio ao projeto “Análise da queima da palha da cana-de-açúcar e suas relações com a
mutagênese humana”.
Duration: 02/2011 à 03/2012
PI: Silveira HC.
PI: Carvalho AL.
10. Rastreamento de biomarcadores e do Papilomavírus humano em raspado celular de
canal anal: correlação com infecção concomitante em colo uterino, cavidade oral e
orofaringe. Funding Agency: FAPESP
Duration: 01/2011 à 12/2012
PI: Longatto Filho A.
11. Implantação do Centro de Prevenção - Edital FINEP - CT-INFRA - 01/2012.
Funding Agency: FINEP
Duration: 2012-2013
PI: Carvalho AL; Longatto Filho A.
12. Decifrando o papel dos pyknons não-codificantes no câncer colorretal.
36
Molecular Oncology Research Center – Barretos Cancer Hospital
Funding Agency: SINF-MDAnderson Cancer Center
Duration: 2012-2014
PI: George Calin, Member: Rui M Reis
13. Avaliação do papel biológico e clínico de alterações nas vias moleculares RAS-MAPK e
PI3K-AKT, em melanomas cutâneos e de mucosa em população Brazileira e comparação
com a população estadunidense.
Funding Agency: FAPESP/fluxo continuo
Duration: 2012-2014
PI: Vazquez VL; Reis RM.
13.2) Pharmaceutical /Biotechnology Industry
1. “Estudo pré-clinico dos potenciais compostos anti-neoplásicos AM10 e AM11”.
Industry: Fitomedicamentos Amazônica
Duration: 2012-2014
PI: Reis RM.
13.3) Individual Grants
13.3.1) Technical Support
1. Edital MCT/CNPq 10/2010 - Apoio Técnico
Funding Agency: CNPq
Duration: 2010-2012
PI: André L. Carvalho
13.3.2) Master Fellowship
1. Beneficiary: Augusto Ludvik Filip Marino
Agency: FAPESP
Duration: 2012-2013
Responsible: Márcia MC Marques Silveira
2. Beneficiary: Nathália Cristina Campanella
Agency: FAPESP
37
Molecular Oncology Research Center – Barretos Cancer Hospital
Duration: 2012-2013
Responsible: Rui M Reis
3. Beneficiary: Flávia Coltri Eguchi
Agency: FAPESP Duration: 2012-2013
Responsible: Silvana Campos
13.3.3) Post-Doc Fellowship
1. Beneficiary: Lucas Bidinotto
Agency: FAPESP
Duration: 2011-2013
Responsible: Rui M Reis
2. Beneficiary: Adriane Feijó Evangelista
Agency: FAPESP
Duration: 2012-2014
Responsible: Márcia MC Marques Silveira
3. Beneficiary: Matias Melen
Agency: CNPq
Duration: 2012-2014
Responsible: André Lopes Carvalho
13.3.4) Exchange Grants
1. Beneficiary: Augusto Ludvik Filip Marino
Agency: Government Canada- Internacional Scholarships (Emerging Leaders in the Americas
Program (ELAP) Duration: February a March de 2012
Country: Canada
Responsible: Márcia MC Marques Silveira
2. Beneficiary: André van Helvoort Lengert
Agency: St. Jude Children’s Research Hospital Duration: July de 2012 a June de 2013.
Country: E.U.A.
Responsible: Daniel Onofre Vidal and Luiz Fernando Lopes.
13.3.5) Search Productivity Grant
38
Molecular Oncology Research Center – Barretos Cancer Hospital
1. Bolsista de Produtividade em Pesquisa 1D
Funding Agency: CNPq
CPOM-Hospital de Câncer de Barretos
Duration: 2011-2014
PI: Adhemar Longatto Filho
2. Bolsista de Produtividade em Pesquisa 2
Funding Agency: CNPq
CPOM-Hospital de Câncer de Barretos
Duration: 2011-2014
PI: Rui M Reis
3. Bolsista de Produtividade em Pesquisa 1D
Funding Agency: CNPq
CPOM-Hospital de Câncer de Barretos
Duration: 2010-2013
PI: André Lopes Carvalho
13.3.6) Visiting Professor
1. Funding Agency: CNPq
CPOM - Hospital de Câncer de Barretos
Visiting Professor: Kari Juhani Syrianny
Duration: 2012-20114
Responsable: Adhemar Longatto Filho
2. Funding Agency: CNPq
CPOM-Hospital de Câncer de Barretos
Visiting Professor: Jeremy Squire
Duration: 2011-2012
Responsable: André Lopes Carvalho
14) Jury participation
14.1) Academic Habilition
1. Rossi BM: Fábio de Oliveira Ferreira - Cirurgia Geral – Faculdade de Medicina da USP –
Substitute member – Dec./2012.
39
Molecular Oncology Research Center – Barretos Cancer Hospital
14.2) PhD
1. Lopes LF: Carolina Salinas de Souza- Investigação do comportamento metastático do
osteossarcoma através de análises de expressão gênica e de alterações genômicas. Tese de
Candidatura ao grau de Doutor em Ciências Médicas submetida à Universidade Federal de
São Paulo - Escola Paulista de Medicina.
2. Marques MMC: Aline Simoneti Fonseca- Assinatura gênica e de microRNAs (miRNAs)
entre adenoma e adenocarcinoma colorretal, Faculdade de Medicina de Ribeirão Preto/USP,
December 07th 2012, Ribeirão Preto, SP, Brazil.
3. Palmero EI: Ingrid Petroni Ewald- Caracterização de um grupo de pacientes em risco para
câncer de mama e ovário hereditários quanto à presença e frequencia de rearranjos genicos
em BRCA Universidade Federal do Rio Grande do Sul, June 11th, 2012, Porto Alegre, Brazil.
4. Reis RM: Marcus Valadao da Silva- Avaliação de potenciais biomarcadores preditores de
beneficio clinico ao mesilato de imatinibe em portadores de GIST metastático. INCA, May
2012, Rio de Janeiro, Brazil.
5. Reis RM: Joana Teresa Lopes Carvalho - O envolvimento de microRNAs em Cancro
Gástrico. Faculdade de Medicina da Universidade do Porto, December 2012, Porto, Portugal
6. Rossi BM: Ligia Petrolini de Oliveira – Correlação entre a presençaa de Splicing aberrante
e mutações sinônimas no gene TP53 em adenocarcinomas colorretais, Hospital A.C.Camargo
– FAP – São Paulo, Dec./2012.
7. Vazquez, V. L: Renato José Affonso Júnior - Estudo da expressão dos genes da matriz
extracelular MMP1, MMP16, COL6A2, THBS-1 E VCAM-1 no tecido tumoral de doentes com
adenocarcinoma colorretal e de suas correlações com os parâmetros clínicos e histológicos
de progressão e disseminação. 2012. - Universidade Federal de São Paulo.
14.3) Master
1. Guimarães DO: Maria de Lourdes Lopes de Oliveira, “Avaliação linfonodal e de seu valor
prognóstico no câncer de reto submetido a tratamento neoadjuvante”, INCA, August 2012,
Rio de Janeiro, Brazil.
2. Reis RM: Arthur William Alvarenga, “O controle da tradução pela via mTOR nos
mecanismos de tumorigenese em gliomas”, ACCamargo, September, 2012, S. Paulo, Brazil.
40
Molecular Oncology Research Center – Barretos Cancer Hospital
3. Reis RM: Ana Luísa Rodrigues Justino – Diagnostico genético das Síndromes associadas a
via de sinalização RAS/MAPK através de sequenciação paralela massiva e estudos de
correlações genótipo-fenótipo. Faculdade de Medicina da Universidade do Porto, December
2012, Porto, Portugal.
4. Rossi BM: Oswaldo William Marques Junior - Colonoscopia de Rastreamento em
Pacientes com Câncer.
15) National and International Collaborations:
15.1) National
- Centro Internacional de Pesquisa e Ensino (CIPE) - Hospital AC Camargo, S. Paulo.
- Faculdade de Medicina da Universidade de São Paulo, S. Paulo.
- INCT-HPV, S. Paulo.
- Instituto de Medicina Integral Professor Fernando Figueira/ Instituto Materno Infantil de
Pernambuco (IMIP), Recife, PE.
- Laboratório de Poluição Atmosférica da Faculdade de Medicina da USP.
- Universidade Federal de Goiás.
- Universidade Federal do Rio Grande do Sul, Porto Alegre.
15.2) International
- Harvard School of Public Health - HSPH, Boston, USA.
- Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Porto,
Portugal.
- Life and Health Science Research Institute (ICVS), University of Minho, Braga, Portugal.
- MDAnderson Cancer Center, Houston, USA.
- The Institute of Cancer Research (ICR), Sutton, UK.
- St. Jude Children’s Research Hospital, Memphis, TN, USA.
16. Visiting Researchers:
- Fábio Marques Almeida, PhD Student, UFG - Universidade Federal de Goiás, Brazil.
- Rui Pereira, Post-Doc. IPATIMUP, Porto, Portugal.
41
Molecular Oncology Research Center – Barretos Cancer Hospital
17. Molecular Diagnostics Center
The Molecular Diagnostics Center is offering to the Barretos Cancer Hospital patients a
variety of tests currently used in the clinical routine in the following areas: Cytogenetics,
Personalized Medicine and Oncogenetics.
18. Future Perspectives
Internal:
- Consolidation of the existing lines of research;
- Strengthen translational research;
-Increased the number of publications and projects by researcher
-Implement a Flow Citometry Service
External:
- Strengthen the partnerships with academic institutes, as well as with pharmaceutical and
biotechnology industry;
- Commercialization of tests from Molecular Diagnostics Center.
42
Molecular Oncology Research Center – Barretos Cancer Hospital